share_log

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target

HC Wainwright & Co. Reiterates Buy on Cullinan Oncology, Maintains $49 Price Target

HC Wainwright & Co.重申買入庫裏南腫瘤學,維持49美元的目標股價
Benzinga ·  2023/06/05 06:30

HC Wainwright & Co. analyst Edward White reiterates Cullinan Oncology (NASDAQ:CGEM) with a Buy and maintains $49 price target.

HC Wainwright&Co.分析師愛德華·懷特重申庫利南腫瘤學(納斯達克:CGEM)的買入,並維持49美元的目標價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論